Preview

Медицинский Совет

Расширенный поиск

Чистогестагенная имплантационная контрацепция (обзор международных клинических рекомендаций)

https://doi.org/10.21518/2079-701X-2015-XX-5-6

Полный текст:

Аннотация

В статье представлен обзор международных клинических рекомендаций по чистогестагенной имплантационной контрацепции. Приведены данные об эффективности, безопасности, рисках и побочных эффектах применения подкожных имплантатов Импланон и Импланон НКСТ.

Об авторе

О. А. Пустотина
Российский университет дружбы народов, Москва
Россия


Список литературы

1. TrusseLL J, Henry N, Hassan F, et al. Burden of unintended pregnancy in the United States: potential savings with increased use of Long-acting reversible contraception. Contraception. 2013, 87: 154-161.

2. Winner B, Peipert JF, Zhao 0 et al. Effectiveness of Long-acting reversible contraception. N Engl J Med, 2012, 366: 1998-2007.

3. American College of Obstetricians and Gynecologists: Long-acting reversible contraception: Implants and intrauterine devices. Obstet Gynecol, 2011, 121: 13 p.

4. Blumenthal P, Gemzell-Danielsson K, Marintcheva-Petrova M. Tolerability And Clinical Safety of IMPLANON®. Eur J Contrac and Reprod Health Care, 2008, 13(S1): 29-36.

5. WHO. Medical eligibility criteria for contraceptive use. Fouth edition, 2009.

6. Graesslin O, Korver T. The contraceptive efficacy of Implanon: a review of clinical trials and marketing experience. Eur J Contracept Reprod Health Care, 2008, 13(Sl.1): 4-12.

7. Kloosterboer HJ, Vonk-Noordegraaf CA, Turpijn EW. Selectivity in progesterone and androgen receptor binding of progestagens used in oral contraceptives. Contraception, 1988, 38(3): 325-332.

8. Makarainen L, van Beek A, Tuomivaara L et al. Ovarian function during the use of a single contraceptive implant: Implanon compared with Norplant. Fertil Steril, 1998, 69: 714-721.

9. Wenzl R, Van Beek A, Schnabel P, et al. Pharmacokinetics of etonogestrel released from the contraceptive implant Implanon. Contraception, 1998, 58: 283-288.

10. Faculty of Sexual & Reproductive Health Care Clinical Guidance. Progestogen-only Implants. Clinical Effectiveness Unit, 2014. http//Www.fsrh. org/pdfs/CEUGuidanceProgestogenOnlylmplants.pdf

11. Meiri K, Brashe V, Orawan K et al. Multicenter randomized clinical trial of one-rod etonogestrel and two-rod levonoergestrel contraceptive implants with nonrandomized coop-er-IUD controls: methodologe and insection data. Contraception, 2013, 87: 113-120.

12. Rekers H. Removal of a fractured Nexplanon: MSD response. J Fam Plann Reprod Health Care, 2013, 39: 67-72.

13. Bensouda-Grimaldi L, Jonville-Bera AP, Beau-Salinas F et al. Insertion problems, removal problems and contraception failures with Implanon. Gynecol Obstet Fertil, 2005, 33: 986-990.

14. Mansour D, Fraser IS, Walling M, et al. Methods of accurate localisation of non-palpable sub-dermal contraceptive implants. J Fam Plann Reprod Health Care, 2008, 34: 9-12.

15. Hatcher RA, Trussel J, Nelson AL et al. Contraceptive Technology. 19th revised ed. New York, NY: Ardent Media, 2007.

16. Lidegaard O, Lokkegaard E, Jensen A, et al. Thrombotic Stroke and Myocardial Infarction with Hormonal Contraception. N Engl J Med, 2012, 366: 22572266.

17. Lidegaard O, Nielsen LH, Skovlund CW, Lokkegaard E. Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10. BMJ, 2012, 344: e2990.

18. Brito MB, Rui A, Ferriani JCM. Effects of the etonogestrel-releasing contraceptive implant inserted immediately postpartum on maternal hemostasis: A randomized controlled trial. Thrombosis Research, 2012, 130: 355-360.

19. Allen RH, Cwiak CA, Kaunitz AM. Contraception in women over 40 years of age. CMAJ, 2013, 185: 565-573.

20. Bitzer J, Tschudin S, Alder J. Acceptability and side-effects of Implanon in Switzerland: A retrospective study by the Implanon Swiss Study Group. Eur J Contracept Reprod Health Care, 2004, 9: 278-284.

21. Dilbaz B, Ozdegirmenci O, Caliskan E et al. Effect of etonogestrel implant on serum lipids, liver function tests and hemoglobin levels. Contraception, 2010, 81: 510-514.

22. Mornar S, Lingtak-Neander C, Mistretta S et al. Pharmacokinetics of the etonogestrel contraceptive implant in obese women. Am J Obstet Gynecol, 2012, 207: e1-e6.

23. Xu H, Wade JA, Peipert JF et al. Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese women. Obstet Gynaecol, 2012, 120: 21-26.

24. Mol BW, Ankum WM, Bossuyt PM, Van der Veen F. Contraception and the risk of ectopic pregnancy: a meta-analysis. Contraception, 1995, 52: 337-344.

25. Reinprayoona D, Taneepanichskula S, Bunyavejchevina S et al. Effects of the etonogestrel-releasing contraceptive implant (Implanon®) on parameters of breastfeeding compared to those of an intrauterine device. Contraception, 2000, 62: 239-246.

26. Darney P, Patel A, Rosen K et al. Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 clinical trials. Fertil Steril, 2009, 91: 1646-1653.

27. Mansour D, Korver T, Marintcheva-Petrova M. The Effects of IMPLANON® on Menstrual Bleeding Patterns. Eur J of Contrac Reprod Health Care, 2008, 13(S1): 13-28.

28. Walch K, Unfried G, Huber J et al. Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis - a pilot study. Contraception, 2009, 79: 29-34.

29. Patel A, Schwarz EB, Society of Family Planning. Cancer and contraception. SFP Guideline. Contraception, 2012, 86: 191-198.

30. Mascarenhas L, van Beek A, Bennink HC, Newton J. A 2-year comparative study of endo-metrial histology and cervical cytology of contraceptive implant users in Birmingham, UK. Hum Reprod, 1998, 13: 3057-3060.

31. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet, 1996, 347: 1713-1727.

32. Pongsatha S, Ekmahachai M, Suntornlimsiri N et al. Bone mineral density in women using the subdermal contraceptive implant Implanon for at least two years. Int J Gynaecol Obstet, 2010, 109: 223-225.

33. Lopez LM, Frimes D, Schulz KF, Curtis KM. Steroidal contraceptives: effect on bone fractures in women. Cochrane Database Syst Rev, 2011, 7: CD006033.

34. National Institute for Health and Care Excellence (NICE). Long-acting Reversible Contraception: The Effective and Appropriate Use of Long-acting Reversible Contraception, 2005. http//guidance.nice.org.uk/CG30

35. Lopez LM, Edelman A, Chen M et al. Progestin-only contraceptives: effects on weight. Cochrane Database Syst Rev., 2013, 7: CD008815.

36. Harrison-Woolrych M, Hill R. Unintended pregnancies with the etonogestrel implant (Impla-non): a case series from postmarketing experience in Australia. Contraception, 2005, 71: 306-308.

37. Singh M, Mansour D, Richardson D. Location and non-palpable Implanon implants with the aid of ultrasound guidance. J Fam Plann Reprod Health Care, 2006, 32: 153-156.

38. Faculty of Sexual & Reproductive Health Care Clinical Guidance. Drug Interactions with Hormonal Contraception, 2011. http//www.fsrh.org/pdfs/ CEUGuidanceDrugInteractionsHormonal.pdf

39. Cooling H, Pauli H. Full term pregnancy with Implanon in situ. J Fam Plann Reprod Health Care, 2006, 32: 204-210.

40. Church E, Sengupta S, Chia KV. The contraceptive implant for long acting reversible contraception in patients undergoing first trimester medical termination of pregnancy. Sex Reprod Health, 2010, 1: 105-109.

41. World Health Organization. Safe Abortion: Technical and Policy Guidance for Health Systems (2nd ed.). Geneva, Switzerland: World Health Organization, 2012.

42. Abdel-aleem H, dArcangues C, Vogelsong K et al. Treatment of vaginal bleeding irregularities induced by progestin only contraceptives. Cochrane Database Syst Rev., 2007(4): CD003449.

43. Faculty of Sexual and Reproductive Health Care. Management of unscheduled bleeding in women using hormonal contraception, 2009.

44. Weisberg E, Hickey M, Palmer D et al. A randomized controlled trial of treatment options for troublesome uterine bleeding in Implanon Users. Hum Reprod, 2009, 24: 1852-1861.

45. Lopez LM, Steiner M, Grimes DA et al. Strategies for communicating contraceptive effectiveness. Cochrane Database Syst Rev, 2013, 4: CD006964.

46. WHO, 2003. Progress in Reproductive health Research, №61.

47. Адамян Л.В. Клиника, диагностика и лечение генитального эндометриоза. Акуш. и гин., 1992, 7: 54-59.

48. Ludicke F1, Sullivan H, Spona J, Elstein M. Dose finding in a low-dose 21-day combined oral contraceptive containing gestodene. Contraception, 2001, Oct., 64(4): 243-8.

49. Walch K, Unfried G, Huber J, Kurz C, Trotsenburg M, Pernicka E et al. Implanon® versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endome-triosis - a pilot study. Contraception, 2009, 79: 29-34.


Просмотров: 85


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)